ArticleBioinformation2026
Multi-epitope design against emerging nipah virus towards peptide vaccine development.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lack of an approved vaccine against Nipah virus (NiV), a highly fatal zoonotic pathogen causing severe neurological and respiratory disease, remains a major global health challenge. Therefore, it is of interest to design a multi-epitope vaccine targeting the NiV phosphoprotein (UniProt ID: Q9IK91). Conserved B-cell, cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte (HTL) epitopes were identified and selected based on antigenicity, immunogenicity and safety. The resulting vaccine construct was evaluated through structural modeling, TLR4 docking, codon optimization and immune simulation analyses. Thus, data shows the favorable stability, strong receptor interaction, efficient expression potential and the ability to elicit robust humoral and cellular immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.